nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—ABCB1—peripheral nervous system neoplasm	0.169	1	CbGaD
Pazopanib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0502	0.129	CbGbCtD
Pazopanib—UGT1A1—Etoposide—peripheral nervous system neoplasm	0.0357	0.0919	CbGbCtD
Pazopanib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0348	0.0895	CbGbCtD
Pazopanib—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0248	0.064	CbGbCtD
Pazopanib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0214	0.0551	CbGbCtD
Pazopanib—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0207	0.0533	CbGbCtD
Pazopanib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.02	0.0514	CbGbCtD
Pazopanib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0196	0.0505	CbGbCtD
Pazopanib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0181	0.0466	CbGbCtD
Pazopanib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0181	0.0466	CbGbCtD
Pazopanib—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0165	0.0426	CbGbCtD
Pazopanib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.0134	0.0345	CbGbCtD
Pazopanib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0125	0.0323	CbGbCtD
Pazopanib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0108	0.0279	CbGbCtD
Pazopanib—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.0105	0.0269	CbGbCtD
Pazopanib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0101	0.0259	CbGbCtD
Pazopanib—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.00809	0.0208	CbGbCtD
Pazopanib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00772	0.0199	CbGbCtD
Pazopanib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0072	0.0185	CbGbCtD
Pazopanib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00707	0.0182	CbGbCtD
Pazopanib—FGFR3—skull—peripheral nervous system neoplasm	0.00568	0.0989	CbGeAlD
Pazopanib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00482	0.0124	CbGbCtD
Pazopanib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00463	0.0119	CbGbCtD
Pazopanib—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00455	0.0117	CbGbCtD
Pazopanib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00424	0.0109	CbGbCtD
Pazopanib—FGFR2—skull—peripheral nervous system neoplasm	0.00372	0.0648	CbGeAlD
Pazopanib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00289	0.00745	CbGbCtD
Pazopanib—FGF1—nerve—peripheral nervous system neoplasm	0.00207	0.0361	CbGeAlD
Pazopanib—FGF1—ganglion—peripheral nervous system neoplasm	0.00205	0.0357	CbGeAlD
Pazopanib—TAOK1—trigeminal ganglion—peripheral nervous system neoplasm	0.00184	0.0321	CbGeAlD
Pazopanib—SH2B3—trigeminal ganglion—peripheral nervous system neoplasm	0.00173	0.0302	CbGeAlD
Pazopanib—Rilpivirine—ABCB1—peripheral nervous system neoplasm	0.00169	1	CrCbGaD
Pazopanib—RIOK2—trigeminal ganglion—peripheral nervous system neoplasm	0.00145	0.0253	CbGeAlD
Pazopanib—RIOK2—parotid gland—peripheral nervous system neoplasm	0.00137	0.0238	CbGeAlD
Pazopanib—PI4KB—trigeminal ganglion—peripheral nervous system neoplasm	0.00128	0.0224	CbGeAlD
Pazopanib—PI4KB—parotid gland—peripheral nervous system neoplasm	0.00121	0.0211	CbGeAlD
Pazopanib—PLK4—Teniposide—Etoposide—peripheral nervous system neoplasm	0.00113	0.332	CbGdCrCtD
Pazopanib—PIP4K2C—trigeminal ganglion—peripheral nervous system neoplasm	0.00113	0.0196	CbGeAlD
Pazopanib—FGFR1—trigeminal ganglion—peripheral nervous system neoplasm	0.00112	0.0195	CbGeAlD
Pazopanib—MAP3K9—cerebellum—peripheral nervous system neoplasm	0.00107	0.0186	CbGeAlD
Pazopanib—PIP4K2C—parotid gland—peripheral nervous system neoplasm	0.00106	0.0185	CbGeAlD
Pazopanib—FGF1—trigeminal ganglion—peripheral nervous system neoplasm	0.00101	0.0175	CbGeAlD
Pazopanib—LCK—trigeminal ganglion—peripheral nervous system neoplasm	0.001	0.0174	CbGeAlD
Pazopanib—FGF1—brainstem—peripheral nervous system neoplasm	0.00089	0.0155	CbGeAlD
Pazopanib—FLT1—trigeminal ganglion—peripheral nervous system neoplasm	0.00088	0.0153	CbGeAlD
Pazopanib—EPHB6—trigeminal ganglion—peripheral nervous system neoplasm	0.00087	0.0152	CbGeAlD
Pazopanib—FGFR2—brainstem—peripheral nervous system neoplasm	0.00084	0.0146	CbGeAlD
Pazopanib—STK10—trigeminal ganglion—peripheral nervous system neoplasm	0.000833	0.0145	CbGeAlD
Pazopanib—FLT1—parotid gland—peripheral nervous system neoplasm	0.00083	0.0145	CbGeAlD
Pazopanib—TAOK3—trigeminal ganglion—peripheral nervous system neoplasm	0.00083	0.0145	CbGeAlD
Pazopanib—EPHB6—parotid gland—peripheral nervous system neoplasm	0.000821	0.0143	CbGeAlD
Pazopanib—TAOK1—cerebellum—peripheral nervous system neoplasm	0.000803	0.014	CbGeAlD
Pazopanib—TAOK3—parotid gland—peripheral nervous system neoplasm	0.000783	0.0136	CbGeAlD
Pazopanib—SH2B3—cerebellum—peripheral nervous system neoplasm	0.000756	0.0132	CbGeAlD
Pazopanib—KDR—trigeminal ganglion—peripheral nervous system neoplasm	0.000744	0.013	CbGeAlD
Pazopanib—MAP2K5—trigeminal ganglion—peripheral nervous system neoplasm	0.000744	0.013	CbGeAlD
Pazopanib—TAOK3—brainstem—peripheral nervous system neoplasm	0.000735	0.0128	CbGeAlD
Pazopanib—CSF1R—trigeminal ganglion—peripheral nervous system neoplasm	0.000726	0.0127	CbGeAlD
Pazopanib—KDR—parotid gland—peripheral nervous system neoplasm	0.000702	0.0122	CbGeAlD
Pazopanib—MAP2K5—parotid gland—peripheral nervous system neoplasm	0.000702	0.0122	CbGeAlD
Pazopanib—KIT—trigeminal ganglion—peripheral nervous system neoplasm	0.00066	0.0115	CbGeAlD
Pazopanib—MAP2K5—brainstem—peripheral nervous system neoplasm	0.000659	0.0115	CbGeAlD
Pazopanib—PDGFRB—trigeminal ganglion—peripheral nervous system neoplasm	0.000644	0.0112	CbGeAlD
Pazopanib—STK16—cerebellum—peripheral nervous system neoplasm	0.000643	0.0112	CbGeAlD
Pazopanib—RIOK2—cerebellum—peripheral nervous system neoplasm	0.000633	0.011	CbGeAlD
Pazopanib—FGFR3—cerebellum—peripheral nervous system neoplasm	0.000633	0.011	CbGeAlD
Pazopanib—BMPR1B—cerebellum—peripheral nervous system neoplasm	0.000627	0.0109	CbGeAlD
Pazopanib—KIT—parotid gland—peripheral nervous system neoplasm	0.000622	0.0108	CbGeAlD
Pazopanib—PDGFRB—parotid gland—peripheral nervous system neoplasm	0.000608	0.0106	CbGeAlD
Pazopanib—PLK4—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000588	0.173	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000588	0.173	CbGdCrCtD
Pazopanib—KIT—brainstem—peripheral nervous system neoplasm	0.000584	0.0102	CbGeAlD
Pazopanib—STK36—cerebellum—peripheral nervous system neoplasm	0.000569	0.00991	CbGeAlD
Pazopanib—PI4KB—cerebellum—peripheral nervous system neoplasm	0.00056	0.00976	CbGeAlD
Pazopanib—LIMK2—cerebellum—peripheral nervous system neoplasm	0.00055	0.00958	CbGeAlD
Pazopanib—PLK4—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000544	0.16	CbGdCrCtD
Pazopanib—PLK4—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000544	0.16	CbGdCrCtD
Pazopanib—PIP4K2C—cerebellum—peripheral nervous system neoplasm	0.000491	0.00856	CbGeAlD
Pazopanib—FGFR1—cerebellum—peripheral nervous system neoplasm	0.000487	0.00849	CbGeAlD
Pazopanib—MAP3K2—cerebellum—peripheral nervous system neoplasm	0.000466	0.00811	CbGeAlD
Pazopanib—FGF1—cerebellum—peripheral nervous system neoplasm	0.000439	0.00765	CbGeAlD
Pazopanib—FGFR2—cerebellum—peripheral nervous system neoplasm	0.000414	0.00722	CbGeAlD
Pazopanib—FLT1—cerebellum—peripheral nervous system neoplasm	0.000384	0.00669	CbGeAlD
Pazopanib—EPHB6—cerebellum—peripheral nervous system neoplasm	0.00038	0.00662	CbGeAlD
Pazopanib—STK10—cerebellum—peripheral nervous system neoplasm	0.000364	0.00633	CbGeAlD
Pazopanib—TAOK3—cerebellum—peripheral nervous system neoplasm	0.000362	0.00631	CbGeAlD
Pazopanib—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	0.000362	0.00631	CbGeAlD
Pazopanib—PDGFRA—cerebellum—peripheral nervous system neoplasm	0.00036	0.00627	CbGeAlD
Pazopanib—ABCG2—parotid gland—peripheral nervous system neoplasm	0.000341	0.00595	CbGeAlD
Pazopanib—KDR—cerebellum—peripheral nervous system neoplasm	0.000325	0.00566	CbGeAlD
Pazopanib—MAP2K5—cerebellum—peripheral nervous system neoplasm	0.000325	0.00566	CbGeAlD
Pazopanib—CSF1R—cerebellum—peripheral nervous system neoplasm	0.000317	0.00552	CbGeAlD
Pazopanib—KIT—cerebellum—peripheral nervous system neoplasm	0.000288	0.00501	CbGeAlD
Pazopanib—PDGFRB—cerebellum—peripheral nervous system neoplasm	0.000281	0.0049	CbGeAlD
Pazopanib—CYP2D6—brainstem—peripheral nervous system neoplasm	0.00022	0.00383	CbGeAlD
Pazopanib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000179	0.00311	CbGeAlD
Pazopanib—ABCG2—cerebellum—peripheral nervous system neoplasm	0.000158	0.00275	CbGeAlD
Pazopanib—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000118	0.000575	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000118	0.000575	CcSEcCtD
Pazopanib—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000118	0.000574	CcSEcCtD
Pazopanib—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000118	0.000574	CcSEcCtD
Pazopanib—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000118	0.000574	CcSEcCtD
Pazopanib—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000118	0.000572	CcSEcCtD
Pazopanib—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000572	CcSEcCtD
Pazopanib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000117	0.000572	CcSEcCtD
Pazopanib—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000571	CcSEcCtD
Pazopanib—Headache—Tretinoin—peripheral nervous system neoplasm	0.000117	0.000571	CcSEcCtD
Pazopanib—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000117	0.000571	CcSEcCtD
Pazopanib—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000117	0.00057	CcSEcCtD
Pazopanib—Pain—Vincristine—peripheral nervous system neoplasm	0.000117	0.000569	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000569	CcSEcCtD
Pazopanib—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000117	0.000569	CcSEcCtD
Pazopanib—Liver function test abnormal—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000568	CcSEcCtD
Pazopanib—Rash—Melphalan—peripheral nervous system neoplasm	0.000117	0.000567	CcSEcCtD
Pazopanib—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000116	0.000567	CcSEcCtD
Pazopanib—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000116	0.000565	CcSEcCtD
Pazopanib—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000564	CcSEcCtD
Pazopanib—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000116	0.000562	CcSEcCtD
Pazopanib—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000562	CcSEcCtD
Pazopanib—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000115	0.000561	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000115	0.000558	CcSEcCtD
Pazopanib—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000556	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000554	CcSEcCtD
Pazopanib—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000113	0.00055	CcSEcCtD
Pazopanib—Face oedema—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000549	CcSEcCtD
Pazopanib—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000112	0.000546	CcSEcCtD
Pazopanib—Nausea—Topotecan—peripheral nervous system neoplasm	0.000112	0.000546	CcSEcCtD
Pazopanib—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000112	0.000544	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000542	CcSEcCtD
Pazopanib—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000111	0.000541	CcSEcCtD
Pazopanib—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000111	0.000541	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.00011	0.000536	CcSEcCtD
Pazopanib—Infection—Etoposide—peripheral nervous system neoplasm	0.00011	0.000536	CcSEcCtD
Pazopanib—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000535	CcSEcCtD
Pazopanib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.00011	0.000534	CcSEcCtD
Pazopanib—Nausea—Melphalan—peripheral nervous system neoplasm	0.00011	0.000534	CcSEcCtD
Pazopanib—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000533	CcSEcCtD
Pazopanib—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000529	CcSEcCtD
Pazopanib—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000109	0.000528	CcSEcCtD
Pazopanib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000108	0.000528	CcSEcCtD
Pazopanib—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000108	0.00189	CbGeAlD
Pazopanib—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000108	0.000526	CcSEcCtD
Pazopanib—Liver function test abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000525	CcSEcCtD
Pazopanib—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000108	0.000525	CcSEcCtD
Pazopanib—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000108	0.000524	CcSEcCtD
Pazopanib—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000521	CcSEcCtD
Pazopanib—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000107	0.000521	CcSEcCtD
Pazopanib—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000521	CcSEcCtD
Pazopanib—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.00052	CcSEcCtD
Pazopanib—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000514	CcSEcCtD
Pazopanib—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000106	0.000514	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000512	CcSEcCtD
Pazopanib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000105	0.000512	CcSEcCtD
Pazopanib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000105	0.00051	CcSEcCtD
Pazopanib—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000509	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000104	0.000508	CcSEcCtD
Pazopanib—Pain—Cisplatin—peripheral nervous system neoplasm	0.000103	0.000503	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000502	CcSEcCtD
Pazopanib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000497	CcSEcCtD
Pazopanib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000102	0.000496	CcSEcCtD
Pazopanib—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000495	CcSEcCtD
Pazopanib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.0001	0.000489	CcSEcCtD
Pazopanib—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	9.97e-05	0.000485	CcSEcCtD
Pazopanib—Paraesthesia—Etoposide—peripheral nervous system neoplasm	9.95e-05	0.000484	CcSEcCtD
Pazopanib—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	9.9e-05	0.000482	CcSEcCtD
Pazopanib—Weight decreased—Epirubicin—peripheral nervous system neoplasm	9.88e-05	0.000481	CcSEcCtD
Pazopanib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	9.87e-05	0.000481	CcSEcCtD
Pazopanib—Somnolence—Etoposide—peripheral nervous system neoplasm	9.85e-05	0.000479	CcSEcCtD
Pazopanib—Asthenia—Vincristine—peripheral nervous system neoplasm	9.81e-05	0.000477	CcSEcCtD
Pazopanib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	9.73e-05	0.000474	CcSEcCtD
Pazopanib—Infestation—Epirubicin—peripheral nervous system neoplasm	9.73e-05	0.000474	CcSEcCtD
Pazopanib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	9.73e-05	0.000474	CcSEcCtD
Pazopanib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	9.71e-05	0.000473	CcSEcCtD
Pazopanib—Rash—Dactinomycin—peripheral nervous system neoplasm	9.65e-05	0.00047	CcSEcCtD
Pazopanib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	9.63e-05	0.000469	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	9.56e-05	0.000465	CcSEcCtD
Pazopanib—Fatigue—Etoposide—peripheral nervous system neoplasm	9.55e-05	0.000465	CcSEcCtD
Pazopanib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	9.49e-05	0.000462	CcSEcCtD
Pazopanib—Jaundice—Epirubicin—peripheral nervous system neoplasm	9.49e-05	0.000462	CcSEcCtD
Pazopanib—Pain—Etoposide—peripheral nervous system neoplasm	9.47e-05	0.000461	CcSEcCtD
Pazopanib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	9.45e-05	0.00046	CcSEcCtD
Pazopanib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	9.38e-05	0.000457	CcSEcCtD
Pazopanib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	9.36e-05	0.000455	CcSEcCtD
Pazopanib—Haematuria—Epirubicin—peripheral nervous system neoplasm	9.28e-05	0.000452	CcSEcCtD
Pazopanib—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	9.22e-05	0.000449	CcSEcCtD
Pazopanib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	9.21e-05	0.000448	CcSEcCtD
Pazopanib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	9.18e-05	0.000447	CcSEcCtD
Pazopanib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	9.14e-05	0.000445	CcSEcCtD
Pazopanib—Nausea—Dactinomycin—peripheral nervous system neoplasm	9.09e-05	0.000442	CcSEcCtD
Pazopanib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	9.06e-05	0.000441	CcSEcCtD
Pazopanib—Dizziness—Vincristine—peripheral nervous system neoplasm	9.04e-05	0.00044	CcSEcCtD
Pazopanib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	9.02e-05	0.000439	CcSEcCtD
Pazopanib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	9.01e-05	0.000438	CcSEcCtD
Pazopanib—Infestation—Doxorubicin—peripheral nervous system neoplasm	9.01e-05	0.000438	CcSEcCtD
Pazopanib—Rash—Alitretinoin—peripheral nervous system neoplasm	8.95e-05	0.000435	CcSEcCtD
Pazopanib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	8.94e-05	0.000435	CcSEcCtD
Pazopanib—Bradycardia—Epirubicin—peripheral nervous system neoplasm	8.9e-05	0.000433	CcSEcCtD
Pazopanib—Headache—Alitretinoin—peripheral nervous system neoplasm	8.89e-05	0.000433	CcSEcCtD
Pazopanib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	8.78e-05	0.000427	CcSEcCtD
Pazopanib—Jaundice—Doxorubicin—peripheral nervous system neoplasm	8.78e-05	0.000427	CcSEcCtD
Pazopanib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	8.78e-05	0.000427	CcSEcCtD
Pazopanib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	8.76e-05	0.000426	CcSEcCtD
Pazopanib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	8.74e-05	0.000425	CcSEcCtD
Pazopanib—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	8.7e-05	0.000423	CcSEcCtD
Pazopanib—Vomiting—Vincristine—peripheral nervous system neoplasm	8.69e-05	0.000423	CcSEcCtD
Pazopanib—Asthenia—Cisplatin—peripheral nervous system neoplasm	8.67e-05	0.000422	CcSEcCtD
Pazopanib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	8.63e-05	0.00042	CcSEcCtD
Pazopanib—Rash—Vincristine—peripheral nervous system neoplasm	8.62e-05	0.00042	CcSEcCtD
Pazopanib—Dermatitis—Vincristine—peripheral nervous system neoplasm	8.61e-05	0.000419	CcSEcCtD
Pazopanib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	8.61e-05	0.000419	CcSEcCtD
Pazopanib—Haematuria—Doxorubicin—peripheral nervous system neoplasm	8.59e-05	0.000418	CcSEcCtD
Pazopanib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	8.59e-05	0.000418	CcSEcCtD
Pazopanib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	8.57e-05	0.000417	CcSEcCtD
Pazopanib—Headache—Vincristine—peripheral nervous system neoplasm	8.57e-05	0.000417	CcSEcCtD
Pazopanib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	8.52e-05	0.000415	CcSEcCtD
Pazopanib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	8.5e-05	0.000414	CcSEcCtD
Pazopanib—Nausea—Alitretinoin—peripheral nervous system neoplasm	8.43e-05	0.00041	CcSEcCtD
Pazopanib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	8.27e-05	0.000403	CcSEcCtD
Pazopanib—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	8.23e-05	0.000401	CcSEcCtD
Pazopanib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	8.17e-05	0.000397	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	8.13e-05	0.000396	CcSEcCtD
Pazopanib—Nausea—Vincristine—peripheral nervous system neoplasm	8.12e-05	0.000395	CcSEcCtD
Pazopanib—Flushing—Epirubicin—peripheral nervous system neoplasm	8.11e-05	0.000395	CcSEcCtD
Pazopanib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	8.11e-05	0.000395	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	8.09e-05	0.000394	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	8.05e-05	0.000392	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	7.99e-05	0.000389	CcSEcCtD
Pazopanib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	7.97e-05	0.000388	CcSEcCtD
Pazopanib—Asthenia—Etoposide—peripheral nervous system neoplasm	7.95e-05	0.000387	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	7.95e-05	0.000387	CcSEcCtD
Pazopanib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	7.93e-05	0.000386	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	7.93e-05	0.000386	CcSEcCtD
Pazopanib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	7.88e-05	0.000383	CcSEcCtD
Pazopanib—Chills—Epirubicin—peripheral nervous system neoplasm	7.84e-05	0.000382	CcSEcCtD
Pazopanib—Pruritus—Etoposide—peripheral nervous system neoplasm	7.84e-05	0.000381	CcSEcCtD
Pazopanib—ABCB1—cerebellum—peripheral nervous system neoplasm	7.79e-05	0.00136	CbGeAlD
Pazopanib—Alopecia—Epirubicin—peripheral nervous system neoplasm	7.72e-05	0.000376	CcSEcCtD
Pazopanib—Vomiting—Cisplatin—peripheral nervous system neoplasm	7.69e-05	0.000374	CcSEcCtD
Pazopanib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	7.66e-05	0.000373	CcSEcCtD
Pazopanib—Rash—Cisplatin—peripheral nervous system neoplasm	7.62e-05	0.000371	CcSEcCtD
Pazopanib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	7.62e-05	0.000371	CcSEcCtD
Pazopanib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	7.61e-05	0.00037	CcSEcCtD
Pazopanib—Erythema—Epirubicin—peripheral nervous system neoplasm	7.61e-05	0.00037	CcSEcCtD
Pazopanib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	7.58e-05	0.000369	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	7.56e-05	0.000368	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	7.5e-05	0.000365	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—peripheral nervous system neoplasm	7.5e-05	0.000365	CcSEcCtD
Pazopanib—Flatulence—Epirubicin—peripheral nervous system neoplasm	7.5e-05	0.000365	CcSEcCtD
Pazopanib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	7.45e-05	0.000363	CcSEcCtD
Pazopanib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	7.34e-05	0.000357	CcSEcCtD
Pazopanib—Dizziness—Etoposide—peripheral nervous system neoplasm	7.32e-05	0.000356	CcSEcCtD
Pazopanib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	7.31e-05	0.000356	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	7.29e-05	0.000355	CcSEcCtD
Pazopanib—Chills—Doxorubicin—peripheral nervous system neoplasm	7.26e-05	0.000353	CcSEcCtD
Pazopanib—Nausea—Cisplatin—peripheral nervous system neoplasm	7.18e-05	0.00035	CcSEcCtD
Pazopanib—Vision blurred—Epirubicin—peripheral nervous system neoplasm	7.17e-05	0.000349	CcSEcCtD
Pazopanib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	7.15e-05	0.000348	CcSEcCtD
Pazopanib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	7.08e-05	0.000345	CcSEcCtD
Pazopanib—Vomiting—Etoposide—peripheral nervous system neoplasm	7.04e-05	0.000343	CcSEcCtD
Pazopanib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	7.04e-05	0.000343	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—peripheral nervous system neoplasm	7.04e-05	0.000343	CcSEcCtD
Pazopanib—Anaemia—Epirubicin—peripheral nervous system neoplasm	7.03e-05	0.000342	CcSEcCtD
Pazopanib—Rash—Etoposide—peripheral nervous system neoplasm	6.98e-05	0.00034	CcSEcCtD
Pazopanib—Dermatitis—Etoposide—peripheral nervous system neoplasm	6.98e-05	0.00034	CcSEcCtD
Pazopanib—Headache—Etoposide—peripheral nervous system neoplasm	6.94e-05	0.000338	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—peripheral nervous system neoplasm	6.94e-05	0.000338	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	6.89e-05	0.000335	CcSEcCtD
Pazopanib—Syncope—Epirubicin—peripheral nervous system neoplasm	6.82e-05	0.000332	CcSEcCtD
Pazopanib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	6.81e-05	0.000331	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	6.77e-05	0.000329	CcSEcCtD
Pazopanib—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	6.69e-05	0.000325	CcSEcCtD
Pazopanib—Cough—Epirubicin—peripheral nervous system neoplasm	6.64e-05	0.000323	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	6.63e-05	0.000323	CcSEcCtD
Pazopanib—Nausea—Etoposide—peripheral nervous system neoplasm	6.58e-05	0.00032	CcSEcCtD
Pazopanib—Hypertension—Epirubicin—peripheral nervous system neoplasm	6.57e-05	0.00032	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	6.51e-05	0.000317	CcSEcCtD
Pazopanib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	6.48e-05	0.000315	CcSEcCtD
Pazopanib—Myalgia—Epirubicin—peripheral nervous system neoplasm	6.48e-05	0.000315	CcSEcCtD
Pazopanib—Chest pain—Epirubicin—peripheral nervous system neoplasm	6.48e-05	0.000315	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	6.43e-05	0.000313	CcSEcCtD
Pazopanib—Dry mouth—Epirubicin—peripheral nervous system neoplasm	6.33e-05	0.000308	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—peripheral nervous system neoplasm	6.31e-05	0.000307	CcSEcCtD
Pazopanib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	6.3e-05	0.000307	CcSEcCtD
Pazopanib—Oedema—Epirubicin—peripheral nervous system neoplasm	6.21e-05	0.000302	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	6.19e-05	0.000301	CcSEcCtD
Pazopanib—Infection—Epirubicin—peripheral nervous system neoplasm	6.17e-05	0.0003	CcSEcCtD
Pazopanib—Cough—Doxorubicin—peripheral nervous system neoplasm	6.14e-05	0.000299	CcSEcCtD
Pazopanib—Shock—Epirubicin—peripheral nervous system neoplasm	6.11e-05	0.000297	CcSEcCtD
Pazopanib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	6.09e-05	0.000296	CcSEcCtD
Pazopanib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	6.08e-05	0.000296	CcSEcCtD
Pazopanib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	6.08e-05	0.000296	CcSEcCtD
Pazopanib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	6.03e-05	0.000294	CcSEcCtD
Pazopanib—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	6e-05	0.000292	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	5.99e-05	0.000292	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	5.99e-05	0.000292	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—peripheral nervous system neoplasm	5.99e-05	0.000292	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	5.95e-05	0.00029	CcSEcCtD
Pazopanib—Anorexia—Epirubicin—peripheral nervous system neoplasm	5.92e-05	0.000288	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	5.86e-05	0.000285	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	0.00028	CcSEcCtD
Pazopanib—Infection—Doxorubicin—peripheral nervous system neoplasm	5.71e-05	0.000278	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	5.66e-05	0.000275	CcSEcCtD
Pazopanib—Shock—Doxorubicin—peripheral nervous system neoplasm	5.65e-05	0.000275	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	5.63e-05	0.000274	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	5.62e-05	0.000274	CcSEcCtD
Pazopanib—Insomnia—Epirubicin—peripheral nervous system neoplasm	5.62e-05	0.000273	CcSEcCtD
Pazopanib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	5.58e-05	0.000272	CcSEcCtD
Pazopanib—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	5.58e-05	0.000271	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	5.55e-05	0.00027	CcSEcCtD
Pazopanib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	5.54e-05	0.000269	CcSEcCtD
Pazopanib—Somnolence—Epirubicin—peripheral nervous system neoplasm	5.52e-05	0.000269	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—peripheral nervous system neoplasm	5.48e-05	0.000267	CcSEcCtD
Pazopanib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	5.47e-05	0.000266	CcSEcCtD
Pazopanib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	5.4e-05	0.000263	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	5.36e-05	0.000261	CcSEcCtD
Pazopanib—Fatigue—Epirubicin—peripheral nervous system neoplasm	5.35e-05	0.000261	CcSEcCtD
Pazopanib—Pain—Epirubicin—peripheral nervous system neoplasm	5.31e-05	0.000258	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	5.23e-05	0.000255	CcSEcCtD
Pazopanib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	5.2e-05	0.000253	CcSEcCtD
Pazopanib—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	5.16e-05	0.000251	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	5.12e-05	0.000249	CcSEcCtD
Pazopanib—Somnolence—Doxorubicin—peripheral nervous system neoplasm	5.11e-05	0.000249	CcSEcCtD
Pazopanib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	5.08e-05	0.000247	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	5.06e-05	0.000246	CcSEcCtD
Pazopanib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	4.99e-05	0.000243	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.96e-05	0.000241	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	4.95e-05	0.000241	CcSEcCtD
Pazopanib—Pain—Doxorubicin—peripheral nervous system neoplasm	4.91e-05	0.000239	CcSEcCtD
Pazopanib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	4.91e-05	0.000239	CcSEcCtD
Pazopanib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	4.7e-05	0.000229	CcSEcCtD
Pazopanib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	4.54e-05	0.000221	CcSEcCtD
Pazopanib—Asthenia—Epirubicin—peripheral nervous system neoplasm	4.45e-05	0.000217	CcSEcCtD
Pazopanib—Pruritus—Epirubicin—peripheral nervous system neoplasm	4.39e-05	0.000214	CcSEcCtD
Pazopanib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	4.25e-05	0.000207	CcSEcCtD
Pazopanib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	4.12e-05	0.000201	CcSEcCtD
Pazopanib—Dizziness—Epirubicin—peripheral nervous system neoplasm	4.11e-05	0.0002	CcSEcCtD
Pazopanib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	4.06e-05	0.000198	CcSEcCtD
Pazopanib—Vomiting—Epirubicin—peripheral nervous system neoplasm	3.95e-05	0.000192	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	3.93e-05	0.000191	CcSEcCtD
Pazopanib—Rash—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.000191	CcSEcCtD
Pazopanib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.00019	CcSEcCtD
Pazopanib—Headache—Epirubicin—peripheral nervous system neoplasm	3.89e-05	0.000189	CcSEcCtD
Pazopanib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	3.8e-05	0.000185	CcSEcCtD
Pazopanib—Nausea—Epirubicin—peripheral nervous system neoplasm	3.69e-05	0.000179	CcSEcCtD
Pazopanib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	3.65e-05	0.000178	CcSEcCtD
Pazopanib—Rash—Doxorubicin—peripheral nervous system neoplasm	3.62e-05	0.000176	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	3.62e-05	0.000176	CcSEcCtD
Pazopanib—Headache—Doxorubicin—peripheral nervous system neoplasm	3.6e-05	0.000175	CcSEcCtD
Pazopanib—Nausea—Doxorubicin—peripheral nervous system neoplasm	3.41e-05	0.000166	CcSEcCtD
Pazopanib—FLT4—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.94e-06	5.12e-05	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.9e-06	5.1e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—MYC—peripheral nervous system neoplasm	8.86e-06	5.07e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.75e-06	5.01e-05	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.74e-06	5.01e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.72e-06	4.99e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—ERBB2—peripheral nervous system neoplasm	8.68e-06	4.97e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—ERBB2—peripheral nervous system neoplasm	8.65e-06	4.96e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	8.65e-06	4.96e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—ERBB2—peripheral nervous system neoplasm	8.59e-06	4.92e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—NRAS—peripheral nervous system neoplasm	8.56e-06	4.9e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.55e-06	4.9e-05	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	8.54e-06	4.89e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	8.53e-06	4.89e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—TP53—peripheral nervous system neoplasm	8.47e-06	4.85e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—ERBB2—peripheral nervous system neoplasm	8.44e-06	4.84e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KNG1—peripheral nervous system neoplasm	8.42e-06	4.83e-05	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	8.39e-06	4.81e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	8.37e-06	4.8e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.29e-06	4.75e-05	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—AKT1—peripheral nervous system neoplasm	8.29e-06	4.75e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.27e-06	4.74e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—HRAS—peripheral nervous system neoplasm	8.26e-06	4.73e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.25e-06	4.73e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—NRAS—peripheral nervous system neoplasm	8.17e-06	4.68e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	8.16e-06	4.68e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.12e-06	4.65e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—HRAS—peripheral nervous system neoplasm	8.1e-06	4.64e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	8.03e-06	4.6e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—ERBB2—peripheral nervous system neoplasm	8.01e-06	4.59e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—ERBB2—peripheral nervous system neoplasm	7.99e-06	4.58e-05	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	7.96e-06	4.56e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.94e-06	4.55e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	7.94e-06	4.55e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	7.93e-06	4.54e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—PTPN11—peripheral nervous system neoplasm	7.92e-06	4.54e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—NRAS—peripheral nervous system neoplasm	7.9e-06	4.53e-05	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.85e-06	4.5e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	7.85e-06	4.5e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.82e-06	4.48e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—ERBB2—peripheral nervous system neoplasm	7.8e-06	4.47e-05	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.71e-06	4.42e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—ERBB2—peripheral nervous system neoplasm	7.63e-06	4.37e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.62e-06	4.37e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.61e-06	4.36e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.55e-06	4.32e-05	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.54e-06	4.32e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—HRAS—peripheral nervous system neoplasm	7.53e-06	4.32e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.48e-06	4.29e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—HRAS—peripheral nervous system neoplasm	7.45e-06	4.27e-05	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.41e-06	4.24e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—GNAS—peripheral nervous system neoplasm	7.36e-06	4.22e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—MYC—peripheral nervous system neoplasm	7.36e-06	4.22e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.32e-06	4.19e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PTPN11—peripheral nervous system neoplasm	7.31e-06	4.19e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.3e-06	4.18e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—HRAS—peripheral nervous system neoplasm	7.29e-06	4.18e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—AKT1—peripheral nervous system neoplasm	7.29e-06	4.18e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.27e-06	4.17e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	7.23e-06	4.14e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—ERBB2—peripheral nervous system neoplasm	7.2e-06	4.12e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	7.15e-06	4.1e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—AKT1—peripheral nervous system neoplasm	7.15e-06	4.1e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	7.11e-06	4.08e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.1e-06	4.07e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.1e-06	4.07e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—NRAS—peripheral nervous system neoplasm	7.08e-06	4.06e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.08e-06	4.06e-05	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.03e-06	4.03e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.01e-06	4.02e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	7e-06	4.01e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—NRAS—peripheral nervous system neoplasm	6.96e-06	3.99e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—HRAS—peripheral nervous system neoplasm	6.95e-06	3.98e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—TP53—peripheral nervous system neoplasm	6.94e-06	3.98e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	6.94e-06	3.97e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.92e-06	3.96e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	6.9e-06	3.95e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	6.7e-06	3.84e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	6.7e-06	3.84e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	6.68e-06	3.83e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.67e-06	3.82e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.66e-06	3.81e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—AKT1—peripheral nervous system neoplasm	6.65e-06	3.81e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—HRAS—peripheral nervous system neoplasm	6.64e-06	3.81e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—NRAS—peripheral nervous system neoplasm	6.6e-06	3.78e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.6e-06	3.78e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—NRAS—peripheral nervous system neoplasm	6.58e-06	3.77e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.58e-06	3.77e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—AKT1—peripheral nervous system neoplasm	6.58e-06	3.77e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—NRAS—peripheral nervous system neoplasm	6.54e-06	3.75e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	6.49e-06	3.72e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—AKT1—peripheral nervous system neoplasm	6.44e-06	3.69e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—NRAS—peripheral nervous system neoplasm	6.42e-06	3.68e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.38e-06	3.65e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.38e-06	3.65e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	6.32e-06	3.62e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—HRAS—peripheral nervous system neoplasm	6.26e-06	3.59e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—ERBB2—peripheral nervous system neoplasm	6.26e-06	3.58e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.24e-06	3.58e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.2e-06	3.55e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	6.18e-06	3.54e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—AKT1—peripheral nervous system neoplasm	6.14e-06	3.52e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—NRAS—peripheral nervous system neoplasm	6.09e-06	3.49e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—MYC—peripheral nervous system neoplasm	6.09e-06	3.49e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—NRAS—peripheral nervous system neoplasm	6.08e-06	3.48e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.02e-06	3.45e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	6.01e-06	3.44e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—MYC—peripheral nervous system neoplasm	5.98e-06	3.43e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.98e-06	3.43e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.95e-06	3.41e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—NRAS—peripheral nervous system neoplasm	5.93e-06	3.4e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.91e-06	3.39e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—AKT1—peripheral nervous system neoplasm	5.86e-06	3.36e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—NRAS—peripheral nervous system neoplasm	5.81e-06	3.33e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.8e-06	3.32e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—HRAS—peripheral nervous system neoplasm	5.78e-06	3.31e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—ERBB2—peripheral nervous system neoplasm	5.78e-06	3.31e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	5.74e-06	3.29e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.73e-06	3.29e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	5.68e-06	3.25e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—MYC—peripheral nervous system neoplasm	5.68e-06	3.25e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	5.66e-06	3.25e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—MYC—peripheral nervous system neoplasm	5.66e-06	3.24e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	5.65e-06	3.24e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.63e-06	3.23e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.61e-06	3.21e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.59e-06	3.21e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.54e-06	3.18e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.53e-06	3.17e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—AKT1—peripheral nervous system neoplasm	5.53e-06	3.17e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—NRAS—peripheral nervous system neoplasm	5.48e-06	3.14e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.46e-06	3.13e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.4e-06	3.1e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.4e-06	3.1e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.36e-06	3.07e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	5.33e-06	3.05e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	5.3e-06	3.03e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.28e-06	3.02e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	5.2e-06	2.98e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HRAS—peripheral nervous system neoplasm	5.18e-06	2.97e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.15e-06	2.95e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.12e-06	2.93e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—AKT1—peripheral nervous system neoplasm	5.1e-06	2.92e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MYC—peripheral nervous system neoplasm	5.1e-06	2.92e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.09e-06	2.92e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.09e-06	2.92e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—HRAS—peripheral nervous system neoplasm	5.09e-06	2.92e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.08e-06	2.91e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.07e-06	2.9e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.04e-06	2.89e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.93e-06	2.83e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.87e-06	2.79e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HRAS—peripheral nervous system neoplasm	4.83e-06	2.77e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HRAS—peripheral nervous system neoplasm	4.82e-06	2.76e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	4.8e-06	2.75e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—HRAS—peripheral nervous system neoplasm	4.78e-06	2.74e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—NRAS—peripheral nervous system neoplasm	4.76e-06	2.73e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—HRAS—peripheral nervous system neoplasm	4.7e-06	2.69e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	4.61e-06	2.64e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.58e-06	2.62e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.58e-06	2.62e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.58e-06	2.62e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—AKT1—peripheral nervous system neoplasm	4.57e-06	2.62e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.55e-06	2.61e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	4.51e-06	2.58e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.5e-06	2.58e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—AKT1—peripheral nervous system neoplasm	4.49e-06	2.57e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.48e-06	2.57e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HRAS—peripheral nervous system neoplasm	4.46e-06	2.55e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HRAS—peripheral nervous system neoplasm	4.45e-06	2.55e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.44e-06	2.54e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—NRAS—peripheral nervous system neoplasm	4.39e-06	2.52e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	4.38e-06	2.51e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.35e-06	2.49e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	4.35e-06	2.49e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—peripheral nervous system neoplasm	4.34e-06	2.49e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.3e-06	2.46e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.27e-06	2.45e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	4.27e-06	2.44e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.26e-06	2.44e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—AKT1—peripheral nervous system neoplasm	4.26e-06	2.44e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.26e-06	2.44e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—AKT1—peripheral nervous system neoplasm	4.25e-06	2.44e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—peripheral nervous system neoplasm	4.25e-06	2.43e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.24e-06	2.43e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.23e-06	2.42e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—AKT1—peripheral nervous system neoplasm	4.22e-06	2.42e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.19e-06	2.4e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—AKT1—peripheral nervous system neoplasm	4.15e-06	2.38e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—peripheral nervous system neoplasm	4.09e-06	2.35e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.05e-06	2.32e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.05e-06	2.32e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—peripheral nervous system neoplasm	4.01e-06	2.3e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.98e-06	2.28e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.96e-06	2.27e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—AKT1—peripheral nervous system neoplasm	3.94e-06	2.26e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—AKT1—peripheral nervous system neoplasm	3.93e-06	2.25e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.84e-06	2.2e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.83e-06	2.2e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—AKT1—peripheral nervous system neoplasm	3.83e-06	2.2e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.75e-06	2.15e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—AKT1—peripheral nervous system neoplasm	3.75e-06	2.15e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.75e-06	2.15e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	3.7e-06	2.12e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	3.68e-06	2.11e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.67e-06	2.1e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	3.61e-06	2.07e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.57e-06	2.05e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.57e-06	2.05e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—AKT1—peripheral nervous system neoplasm	3.54e-06	2.03e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.53e-06	2.02e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.5e-06	2.01e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.5e-06	2e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—peripheral nervous system neoplasm	3.48e-06	2e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	3.48e-06	1.99e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.44e-06	1.97e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.35e-06	1.92e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.29e-06	1.88e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.26e-06	1.87e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.26e-06	1.87e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—peripheral nervous system neoplasm	3.22e-06	1.84e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.12e-06	1.79e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.11e-06	1.78e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.08e-06	1.76e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—AKT1—peripheral nervous system neoplasm	3.07e-06	1.76e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.96e-06	1.69e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.93e-06	1.68e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.9e-06	1.66e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.87e-06	1.65e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.87e-06	1.64e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	2.84e-06	1.63e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—AKT1—peripheral nervous system neoplasm	2.84e-06	1.63e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.81e-06	1.61e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	2.79e-06	1.6e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.76e-06	1.58e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.75e-06	1.58e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.75e-06	1.57e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AKT1—peripheral nervous system neoplasm	2.71e-06	1.56e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AKT1—peripheral nervous system neoplasm	2.49e-06	1.43e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.48e-06	1.42e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.43e-06	1.39e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.35e-06	1.35e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	2.3e-06	1.32e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.25e-06	1.29e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.99e-06	1.14e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	1.43e-06	8.19e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	1.25e-06	7.13e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.17e-06	6.72e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	9.94e-07	5.7e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	7.67e-07	4.4e-06	CbGpPWpGaD
